Biomoda and TriCore Reference Laboratories Announce Collaboration on Clinical Research Studies

Published: Sep 17, 2007

ALBUQUERQUE, N.M., Sept. 17 /PRNewswire-FirstCall/ -- Biomoda, Inc. ( of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced today TriCore Reference Laboratories of Albuquerque will conduct assay preparation, testing and analysis of Biomoda's proprietary test for detection of early lung cancer as part of the company's clinical programs.

"Our work with TriCore is an essential part of the transfer of technology and the validation work of our assay that we will be conducting through additional tests scheduled to begin this year," said John Cousins, President of Biomoda. "Our relationship with TriCore has expanded over the past several years from preparing slides from sputum samples to conducting complete diagnostic assay protocol. TriCore is the premier reference laboratory in the Southwest."

TriCore ( is a regional medical reference laboratory providing diagnostic testing for physicians, hospitals, and other healthcare providers. In addition to being a full-service reference laboratory offering more than 1,500 diagnostic tests, TriCore is a regional leader in research and clinical trials for universities, medical diagnostics companies and international biotech firms.

"TriCore's expertise and experience in developing and performing diagnostic tests will be a significant advantage in furthering Biomoda's technology transfer and commercialization efforts," said Cousins. "TriCore will be part of a team of expert companies working with Biomoda."

Biomoda's technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.

Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

Cautionary Statement: Investors should be aware that trading in the company's stock through market makers and quotation on the OTC Bulletin Board entails risk. Due in part to the decreased trading price of our stock and reduced analyst coverage, the trading price may change quickly, and market makers may not be able to execute trades quickly. Please contact your broker if you have further questions about executing trades. "Safe Harbor" Statement: This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are naturally subject to uncertainty and changes in circumstances. Actual results may vary materially from expectations contained herein. Biomoda is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Biomoda, Inc.

CONTACT: John Cousins, +1-505-821-0875, for Biomoda, Inc.

Back to news